相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Propranolol as therapy for cerebral cavernous malformations: a cautionary note
Robert Shenkar et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression
Phillip M. Kemp Bohan et al.
CANCER PREVENTION RESEARCH (2021)
Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models
Wenqing Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Aileen A. Ren et al.
NATURE (2021)
Cerebral Cavernous Malformation From Mechanism to Therapy
Daniel A. Snellings et al.
CIRCULATION RESEARCH (2021)
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations
Matthieu Peyre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial
Silvia Lanfranconi et al.
TRIALS (2020)
Safety and ef ficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor -positive breast cancer and the of biomarkers
Zongbi Yi et al.
BREAST (2020)
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)
Sean P. Polster et al.
NEUROSURGERY (2019)
Rapalogs Potential as Practical Alternatives to Rapamycin
Ahmed F. Abdel-Magid
ACS Medicinal Chemistry Letters (2019)
Cavernous angiomas: deconstructing a neurosurgical disease
Issam A. Awad et al.
JOURNAL OF NEUROSURGERY (2019)
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Mikhail Blagosklonny
CELL DEATH & DISEASE (2019)
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
Petra Hillmann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Sean P. Polster et al.
NEUROSURGERY (2019)
Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation
Julie E. Strychowsky et al.
LARYNGOSCOPE (2018)
Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study
Janet Bee et al.
THORAX (2018)
Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
L. Lo Muzio et al.
ORAL DISEASES (2018)
Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
Hee-Young Yoon et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations
Robert Shenkar et al.
STROKE (2017)
Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
Ming-Tao Yang et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel
Amy Akers et al.
NEUROSURGERY (2017)
Estimates of local biodiversity change over time stand up to scrutiny
Mark Vellend et al.
ECOLOGY (2017)
Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system
Sebastian I. Arriola Apelo et al.
AGING CELL (2016)
Potential therapeutic effects of mTOR inhibition in atherosclerosis
Ammar Kurdi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Rapamycin Normalizes Serum Leptin by Alleviating Obesity and Reducing Leptin Synthesis in Aged Rats
Philip J. Scarpace et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2016)
Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice
Sebastian I. Arriola Apelo et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2016)
Men and mice: Relating their ages
Sulagna Dutta et al.
LIFE SCIENCES (2016)
Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex
Nicholas Rensing et al.
EPILEPSIA (2015)
Everolimus and sirolimus in transplantation-related but different
Jost Klawitter et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin
Irina G. Popovich et al.
CANCER BIOLOGY & THERAPY (2014)
Comparison of rapamycin schedules in mice on high-fat diet
Olga V. Leontieva et al.
CELL CYCLE (2014)
Low-Dose Rapamycin ( Sirolimus) Effects in Autosomal Dominant Polycystic Kidney Disease: An Open-Label Randomized Controlled Pilot Study
William E. Braun et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis
David A. McDonald et al.
HUMAN MOLECULAR GENETICS (2014)
Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Daniel A. Morgenstern et al.
PEDIATRIC BLOOD & CANCER (2014)
Strategies for the management of adverse events associated with mTOR inhibitors
Bruce Kaplan et al.
TRANSPLANTATION REVIEWS (2014)
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
Gianluigi Zaza et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
Katsutoshi Ando et al.
RESPIRATORY INVESTIGATION (2013)
Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial
D. Mark Davies et al.
CLINICAL CANCER RESEARCH (2011)
Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Richard A. Miller et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2011)
Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy
Josep M. Cruzado et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Francis X. McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and Safety of Sirolimus and Everolimus in Heart Transplant Patients: A Retrospective Analysis
B. Baur et al.
TRANSPLANTATION PROCEEDINGS (2011)
A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis
Brandon N. Phillips et al.
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION (2011)
Familial versus Sporadic Cavernous Malformations: Differences in Developmental Venous Anomaly Association and Lesion Phenotype
T. A. Petersen et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Species Differences in Mechanism-Based Inactivation of CYP3A in Humans, Rats and Mice
Sasitorn Aueviriyavit et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Body Surface Area Prediction in Normal, Hypermuscular, and Obese Mice
Michael C. Cheung et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
David E. Harrison et al.
NATURE (2009)
Management of Side Effects of Sirolimus Therapy
Giovanni Stallone et al.
TRANSPLANTATION (2009)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients
Gero Tenderich et al.
CLINICAL TRANSPLANTATION (2007)
The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy
Robert T. Abraham et al.
CLINICAL CANCER RESEARCH (2007)
Spectrum of genotype and clinical manifestations in cerebral cavernous malformations
Judith Gault et al.
NEUROSURGERY (2006)
Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance
Wilfred Lieberthal et al.
TRANSPLANTATION (2006)
Body surface area in normal-weight, overweight, and obese adults. A comparison study
J Verbraecken et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Sirolimus - The evidence for clinical pharmacokinetic monitoring
SB Stenton et al.
CLINICAL PHARMACOKINETICS (2005)
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations
F Bergametti et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants
DR Nelson et al.
PHARMACOGENETICS (2004)
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations
CL Liquori et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Estimating the starting dose for entry into humans: principles and practice
BG Reigner et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
mTOR inhibitors: An overview
P Neuhaus et al.
LIVER TRANSPLANTATION (2001)
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
AS MacDonald
TRANSPLANTATION (2001)
Rapamycin in transplantation: A review of the evidence
RN Saunders et al.
KIDNEY INTERNATIONAL (2001)
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
BD Kahan
LANCET (2000)
Pharmacokinetics and metabolism of sirolimus
HL Gallant-Haidner et al.
THERAPEUTIC DRUG MONITORING (2000)
分享论文
